NZ523676A - Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease - Google Patents
Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel diseaseInfo
- Publication number
- NZ523676A NZ523676A NZ523676A NZ52367601A NZ523676A NZ 523676 A NZ523676 A NZ 523676A NZ 523676 A NZ523676 A NZ 523676A NZ 52367601 A NZ52367601 A NZ 52367601A NZ 523676 A NZ523676 A NZ 523676A
- Authority
- NZ
- New Zealand
- Prior art keywords
- irritable bowel
- cetyl
- treat
- bowel disease
- myristate
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A cetyl myristate and cetyl palmitate mixture, useful for the treatment or prophylaxis of irritable bowel syndrome and/or irritable bowel disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ523676A NZ523676A (en) | 2001-05-11 | 2001-05-11 | Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ52298101A NZ522981A (en) | 2001-05-11 | 2001-05-11 | Treating irritable bowel syndrome or disease |
NZ523676A NZ523676A (en) | 2001-05-11 | 2001-05-11 | Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ523676A true NZ523676A (en) | 2003-03-28 |
Family
ID=19928944
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ523676A NZ523676A (en) | 2001-05-11 | 2001-05-11 | Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease |
NZ52298101A NZ522981A (en) | 2001-05-11 | 2001-05-11 | Treating irritable bowel syndrome or disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ52298101A NZ522981A (en) | 2001-05-11 | 2001-05-11 | Treating irritable bowel syndrome or disease |
Country Status (1)
Country | Link |
---|---|
NZ (2) | NZ523676A (en) |
-
2001
- 2001-05-11 NZ NZ523676A patent/NZ523676A/en not_active IP Right Cessation
- 2001-05-11 NZ NZ52298101A patent/NZ522981A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ522981A (en) | 2005-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN04113A1 (en) | 3-รข-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
MY136707A (en) | Thrombopoietin mimetics | |
GB0005251D0 (en) | Therapeutic compounds | |
DE69831506D1 (en) | 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe | |
MXPA02011288A (en) | Substituted thioacetamides. | |
HK1069316A1 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
GB0225475D0 (en) | Therapeutic agents | |
GB0025173D0 (en) | Therapeutic agents | |
TW200505434A (en) | Therapeutic treatment | |
MXPA03001645A (en) | Compositions and methods for the diagnosis and treatment of tumor. | |
TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
GB0225474D0 (en) | Therapeutic agents | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
AU5624699A (en) | Use of 5ht-6 antagonists | |
BR0309095A (en) | Use of osteoprotegerin for the treatment and / or prevention of fibrotic disease. | |
IL110943A (en) | Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders | |
EP0909561A3 (en) | Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder | |
CA2408537A1 (en) | Treating irritable bowel syndrome or disease | |
DE60013486D1 (en) | LINKS | |
RS8504A (en) | Novel cyclohexil sulphones | |
MXPA02009705A (en) | New combination of a betablocker and a cholesterol lowering agent. | |
GB0020504D0 (en) | Therapeutic method | |
HUP0002836A2 (en) | Use of macrocyclic bis(3,3'-indolyl)-maleimide derivatives for the preparation of pharmaceutical compositions treating skin disorders | |
MXPA02011511A (en) | USE OF (plus;) agr; (2, 3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDIN EMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS. | |
MY124071A (en) | Treatment of viral disease in swine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
ERR | Error or correction |
Free format text: THE FILED DATE HAS BEEN CORRECTED TO 12/05/2000 Effective date: 20131025 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 11 MAY 2021 BY LEA SKYLLERSTEDT Effective date: 20140430 |
|
EXPY | Patent expired |